Skip to content

Clinical study of bupivacaine liposomal quadratus lumborum block versus epidural morphine in post-cesarean analgesia

Clinical study of bupivacaine liposomal quadratus lumborum block versus epidural morphine in post-cesarean analgesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109945
Enrollment
Unknown
Registered
2025-09-28
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Liposomal Bupivacaine Quadratus Lumborum Block Group:0.44% bupivacaine liposomal bilateral quadratus lumbarum block, 30 ml on each side
Epidural Morphine group:10 ml of normal saline solution containing 2 mg of morphine through the epidural catheter

Sponsors

Jiangsu Province People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 or above; 2. ASA I to III; 3. Patients who underwent elective subarachnoid block anesthesia cesarean section for full-term pregnancy; 4. Patients who can understand the content of the score, complete the questionnaire and follow the study protocol.

Exclusion criteria

Exclusion criteria: 1. Patients with neuropathy or chronic pain syndrome in the past; 2. Patients with a history of allergy to local anesthetics or one of the study drugs (liposomal bupivacaine, acetaminophen and butofino tartrate); 3. Patients with severe liver and kidney insufficiency (Child-Pugh score grade C or above or creatinine value > 1.5 times the upper limit of normal or GFR < 40ml/min); 4. Patients with mental or cognitive impairment; 5. History of drug or alcohol abuse, including long-term opioid use; 6. Those with contraindications to quadratus lumborum block and subarachnoid block (including puncture site infection, bleeding tendency, allergy to local anesthetics, refusal, anatomical abnormalities, hemodynamic instability, and known neurological diseases); 7. Patients using anticoagulants or aspirin; 8. Patients with a history of gastrointestinal ulcers; Patients with cardiac disease in the mother and infant (including severe arrhythmias, myocarditis, ischemic heart disease, valve disease, etc.).

Design outcomes

Primary

MeasureTime frame
Total cumulative opioid consumption, expressed as morphine equivalent dose;

Secondary

MeasureTime frame
Number of analgesic pump pressing times and morphine consumption equivalents;NRS scores during rest and movement;The first time an interval of intravenous supplemental analgesia is required;Brief Pain Inventory scale score at 72h after surgery;Time to first spontaneous voiding;First time to get out of bed successful;Incidence of adverse events (including somnolence, respiratory depression, nausea, vomiting, pruritus, urinary retention, hypotension, and puncture site hematoma);

Countries

China

Contacts

Public ContactMa Rong

Jiangsu Province People's Hospital

mrongerr@163.com+86 138 5156 1882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026